|
業務類別
|
Biotechnology |
|
業務概覽
|
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF inductionand improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases. |
| 公司地址
| 26 Landsdowne Street, Cambridge, MA, USA, 02139 |
| 電話號碼
| +1 617 651-8851 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.fulcrumtx.com |
| 員工數量
| 55 |
| Mr. Alex C. Sapir |
Director, President and Chief Executive Officer |
美元 650.00K |
24/02/2026 |
| Mr. Alan A. Musso |
Chief Financial Officer and Treasurer |
美元 457.50K |
24/02/2026 |
| Mr. Curtis G. Oltmans |
Chief Legal Officer |
美元 454.00K |
30/04/2025 |
| Mr. Gregory Tourangeau |
Vice President, Finance, Controller and Principal Accounting Officer |
-- |
24/02/2026 |
|
|
| Ms. Rachel K. King |
Independent Director |
24/02/2026 |
| Mr. James A. Geraghty |
Independent Director |
24/02/2026 |
| Dr. Robert J. Gould, PhD |
Director |
24/02/2026 |
| Mr. Alex C. Sapir |
Director, President and Chief Executive Officer |
24/02/2026 |
| Ms. Katina Dorton, J.D.,M.B.A. |
Independent Director |
24/02/2026 |
| Dr. Alan Ezekowitz, M.D.,PhD |
Independent Director |
24/02/2026 |
| Ms. Kate Haviland, M.B.A. |
Chairman of the Board |
24/02/2026 |
| Ms. Sonja Banks |
Independent Director |
24/02/2026 |
| Mr. Colin Hill |
Independent Director |
24/02/2026 |
|
|
|
|
